The Company

Avilex Pharma is a spin out from the University of Copenhagen, founded by Professor Kristian Strømgaard and Assis. Prof. Anders Bach of the Department of Drug Design and Pharmacology, with investment from Novo Seeds (part of Novo A/S) and Wellcome Trust.

Avilex won the  ‘The Copenhagen Spin-outs Award for most promising company/project 2012-13
and has been nominated for ‘Falling Walls Science Start-Up of the Year 2013

 

BOARD/MANAGEMENT

Avilex_Kristian_Strømgaard

CEO, CSO

Kristian Strømgaard

PhD, Professor

Avilex_Mikael_Thomsen

CDO

Mikael Thomsen

PhD

Ian

CBO

Ian Laquian

MBA

Avilex_Anders_Bach

CONSULTANT

Anders Bach

PhD, Assis. Prof.

BOARD OF DIRECTORS

Avilex_Raymond_Hill

Raymond Hill

PhD, Chairman of the Board

Morten

Morten G. Døssing

Principal, Novo Seeds

Avilex_Mark_Treherne

Mark Treherne

PhD, Non-Executive Board Member

New paradigm in clinical stroke studies

Clinical studies of ischemic stroke are currently undergoing exciting changes, in particular with the ability of early onset treatment. Recently seminal examples of this have been published including the PHANTOM-S, MR CLEAN, and FAST-MAG studies. This provides an exciting perspective for new treatment of ischemic stroke.

Getting chemistry and biology to communicate

Copenhagen Spin-outs features an in-depth profile of Avilex Pharma and its CEO/CSO Kristian Strømgaard.

Read More

© Copyright 2019 Avilex Pharma. All rights reserved.
Avilex Pharma, Ole Maaløes Vej 3, 2200 Copenhagen, DK